Abstracts tagged "interferon"

Abstract Number: 0919 • ACR Convergence 2024
The Effects of CB2R Activation on Inflammatory Pathways in Dermatomyositis
Rohan Dhiman¹, Ahmed Eldaboush², Navin Vijayarangan³, Darae Kang³, Caroline Stone², Nilesh Kodali³, DeAnna Diaz³ and Victoria Werth⁴, ¹University of Pennsylvania, Newport Coast, CA, ²University of Pennsylvania, Philadelphia, PA, ³PennMedicine, Philadelphia, ⁴Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Previous in vitro investigations done by our group into the utility of CB2R activation to treat dermatomyositis (DM) used stimulants that activated pathways not…
Abstract Number: 1762 • ACR Convergence 2024
Multi-omic Analysis Defines Heterogeneous and Cell Specific Type I Interferon Signalling in Juvenile-onset SLE Patients Associated with Biomarkers of Cardiovascular Risk
Junjie Peng, Thomas McDonnell, Elizabeth Jury, Coziana Ciurtin and George Robinson, University College London, London, United Kingdom
Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is an autoimmune disease characterised by chronic inflammation, multi-organ damage, and/or death. Despite their young age, jSLE patients have…
Abstract Number: 2376 • ACR Convergence 2024
Systemic Lupus Erythematosus Patients Exhibit Dynamic Changes in Disease-Associated Transcripts Following Total Knee or Total Hip Arthroplasty
David Fernandez¹, Stephen Batter¹, Deanna Jannat-Khah¹, Mikhail Olferiev¹, Insa Mannstadt², Mark Figgie¹, Peter Sculco¹, Jason Blevins¹, Caroline Siegel¹, Dina Greenman¹, Kyriakos Kirou¹ and Susan Goodman³, ¹Hospital for Special Surgery, New York, NY, ²Columbia University VP&S, New York, NY, ³Hospital for Special Surgery, New York 10025, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) undergoing total hip arthroplasty and total knee arthroplasty (THA and TKA) experience higher complication rates than osteoarthritis (OA)…
Abstract Number: 0951 • ACR Convergence 2024
A Feedback Loop Involving mtDNA, Platelets and Neutrophil Extracellular Traps Amplifies Inflammation in Systemic Sclerosis
Stavros Giaglis¹, Diego Kyburz² and Ulrich Walker³, ¹Experimental Rheumatology Laboratory, University of Basel, Basel, Switzerland, ²University Hospital Basel, Basel, Switzerland, ³Basel University Hospital, Basel, Switzerland
Background/Purpose: Mitochondria are essential eucaryotic cell organelles with several bacterial features, such as a double-stranded circular genome with hypomethylated CpG areas (1). A fundamental role of…
Abstract Number: 1766 • ACR Convergence 2024
STAT2-Associated Type I Interferonopathy: A Masquerade of Infectious Susceptibility
Conor Gruber¹, Angelica Lee², Sofija Buta², Marta Martin Fernandez², Veronique Houdouin³, Jean-Laurent Casanova⁴, Alice Hadchouel⁵, Jacinta Bustamante⁵ and Dusan Bogunovic², ¹Mount Sinai Hospital, New York, NY, ²Columbia University, New York, NY, ³Robert Debré Hospital, Paris, France, ⁴Rockefeller University, New York, NY, ⁵Hôpital Necker-Enfants Malades, Paris, France
Background/Purpose: Type I IFN (IFN-I) signaling is a potent inflammatory pathway fundamental to antiviral immunity. In humans, loss of IFN-I activity underlies severe viral disease,…
Abstract Number: 2385 • ACR Convergence 2024
Increased Type I Interferon Inducible Genes Expression in the Peripheral Blood of Patients Presenting Cutaneous Lupus Erythematosus Manifestations
Anastasia- Bilio Chronopoulou¹, Maria Gerochristou², Sylvia Raftopoulou³, Alexander Stratigos⁴ and Clio Mavragani⁵, ¹National and Kapodistrian University of Athens, Athens, Greece, ²Andreas Syggros Hospital, National and Kapodistrian University of Athens, Athens, Greece, ³Molecular and Applied Physiology Unit, Department of Physiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece, ⁴1st Department of Dermatology-Venereology, Faculty of Medicine, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece, ⁵Department of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece
Background/Purpose: Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disease characterized by a spectrum of cutaneous manifestations resulting from immune dysregulation and inflammation. While…
Abstract Number: 0954 • ACR Convergence 2024
Increased Proliferating Natural Killer Cells Exhibit an Aberrant Pro-Inflammatory Gene Signature in Systemic Sclerosis Patients
Pietro Bearzi¹, Elena Pachera², Sophie Wagner³, Astrid Hofman⁴, Lumeng Li⁴, Laura Much⁴, Mike Becker⁵, Kristina Bürki⁴, Luca Navarini⁶, Anna-Maria Hoffmann-Vold⁷, Roberto Giacomelli⁸ and Oliver Distler⁹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³University of Zurich, Schlieren, Switzerland, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁶Rheumatology, Immunology and Clinical Medicine Unit, Department of Medicine, University of Rome "Campus Bio-Medico", Rome, Italy, ⁷Oslo University Hospital, Oslo, Norway, ⁸Rheumatology, Immunology and Clinical Medicine Unit, Department of Medicine, University of Rome "Campus Bio-Medico", Roma, Italy, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Recent transcriptomic data suggest a prominent involvement of innate immune cells in the pathogenesis of SSc. In this regard, contrasting data on NK cells…
Abstract Number: 1768 • ACR Convergence 2024
A Potential Role of Longstanding IL-18 Stimulation in the Susceptibility for Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis
Greta Rogani¹, Remco Erkens¹, Marein Putmans¹, Rianne Scholman¹, Jorg van Loosdregt² and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²University Medical Center Utrecht, La Jolla, CA
Background/Purpose: Macrophage Activation Syndrome (MAS) is a pathologic condition of immune hyperactivation, which occurs in 10-30% of cases of Still’s Disease (SD), the spectrum of…
Abstract Number: 2397 • ACR Convergence 2024
Increase of IL10 and IFNa2 Are Associated to Clinical Activity in Systemic Lupus Erythematous Patients
Elena Grau García¹, Marta De la Rubia Navarro², Samuel Leal Rodriguez¹, José Ivorra-Cortés³, Carmen Riesco Barcena⁴, Anderson Huaylla Quispe⁴, Laura Mas Sánchez⁵, Pablo Muñoz Martínez⁶, Daniel Ramos Castro⁴, Alba Torrat noves⁷, Iago Alcantara Alvarez², Belén Villanueva Mañés², Miguel Simeo Vinaixa², Andrés Pérez Hurtado⁴ and Jose A Román-Ivorra⁸, ¹HUP La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁴Rheumatology Department. HUP La Fe, Valencia, Spain, ⁵Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁶Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by deregulation of cytokine production. Interferon (IFN) is a proinflamatory cytokine considered as a key…
Abstract Number: 0970 • ACR Convergence 2024
Deubiquitylase (DUB) BRCC36 Isopeptidase Complex (BRISC) Inhibitors Prevent IFNAR1 Deubiquitination to Restore Natural Type I IFN Response in Autoimmunity
Rebecca Ross¹, Poli Adi Narayanna Reddy², Joseph Salvino², Elton Zeqiraj³ and Francesco Del Galdo³, ¹Medicine and Health, University of Leeds, Leeds, United Kingdom, ²The Wistar Institute, Philadelphia, PA, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Increased Type I IFN activation plays a key role in Scleroderma (SSc), Systemic Lupus Erythematosus and Inflammatory Myositis. Deubiquitylase (DUB) BRCC36 isopeptidase complex (BRISC)…
Abstract Number: 1770 • ACR Convergence 2024
Assessing S100A4 and Myofibroblast Phenotypes in the Pathogenesis of Cardiac and Cutaneous Neonatal Lupus
Nalani Sachan¹, Christina Firl², Philip Carlucci³, Nicola Fraser², Robert Clancy⁴ and Jill Buyon⁵, ¹NYU Grossman School of Medicine, New York, NY, ²NYU Langone Health, New York, NY, ³New York University School of Medicine, New York, NY, ⁴Columbia University Medical Center, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY
Background/Purpose: Neonatal lupus (NL), driven by fetal exposure to maternal anti-SSA/Ro autoantibodies, typically results in permanent cardiac manifestations in utero and/or a transient rash postnatally.…
Abstract Number: 2423 • ACR Convergence 2024
Associations Between Cytometric Interferon Signature and Clinical Response in a Cohort of Anifrolumab-treated Patients with Lupus
Alice Horisberger¹, Katharina Shaw², Eilish Dillon³, Kathryne Marks⁴, Rochelle Castillo⁵, Ifeoluwakiisi Adejorin⁶, Kimberly Hashemi⁴, Karen Costenbader⁷, Avery LaChance⁸, Ruth Ann Vleugels⁵ and Deepak Rao¹, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Perelman School of Medicine at the University of Pennsylvania, Merion Station, PA, ³University of Massachusetts Boston, Yarmouth, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Woman's Hospital, Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁸Brigham and Women's Hospital, Jamaica Plain, MA
Background/Purpose: Anifrolumab, a monoclonal antibody targeting type I interferon (IFN-I) receptor subunit 1, was recently approved for the treatment of systemic lupus erythematosus (SLE) and…
Abstract Number: 0001 • ACR Convergence 2024
Type I Interferon and Anifrolumab Effects on Bone Marrow and Blood Plasma Cells in Systemic Lupus Erythematosus
Diana Alzamareh¹, Nida Pellett², Daria Krenitsky², Wesley Durrett¹, Javier Rangel-Moreno¹, Jennifer Anolik² and Jennifer Barnas¹, ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of pathogenic anti-nuclear antibodies (ANA) by plasma cells (PC). Importantly, long-lived plasma…
Abstract Number: 1150 • ACR Convergence 2024
Increased ISG15 Expression in Peripheral Blood from Patients with Positive Dermatomyositis Related Specific Autoantibodies
Sylvia Raftopoulou¹, Nikolaos Michalakeas¹, Maria Gerochristou², Nikolaos Marketos¹, Charalampos Skarlis¹ and Clio Mavragani³, ¹Molecular and Applied Physiology Unit, Department of Physiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece, ²Andreas Syggros Hospital, National and Kapodistrian University of Athens, Athens, Greece, ³Department of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterised by muscle inflammation (myositis) and weakness, impacting various organ systems. Clinical subtypes include dermatomyositis (DM), antisynthetase syndrome (ASyS),…
Abstract Number: 1772 • ACR Convergence 2024
Modeling and Predicting HLH Through Measurement of Immune Synapse Duration, Cytokine Production, and Target Cell Death
Anastasia Frank-Kamenetskii¹, Jemy Varghese², Jeremy Morrissette³, Hannah Klinghoffer⁴, Caroline Diorio⁵, Janis Burkhardt⁶ and Scott Canna², ¹CHOP/UPENN, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania - Perelman School of Medicine, Philadelphia, PA, ⁴The Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Division of Pediatric Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, ⁶The Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: Hyperinflammation is a life-threatening systemic inflammatory state most commonly associated with Hemophagocytic Lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS), but observed in nearly all inflammatory…

« Previous Page
1
…
3
4
5
6
7
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].